MedTrace Logo

A Study to Evaluate 20vPnC in Healthy Chinese Infants

NCT07754539 · Status: RECRUITING · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 1250

Last updated 2026-08-10

No results posted yet for this study

Summary

The purpose of this study is to evaluate a study vaccine called 20-valent pneumococcal conjugate vaccine (20vPnC). The study will assess whether the study vaccine is safe to use in healthy infants. It will also evaluate if the study vaccine can help the body make antibodies (known as immune response). These antibodies help protect against 20 types of pneumococcal bacteria. The study will compare 20vPnC with 13vPnC (control vaccine), which is approved for use in infants.

The study is seeking participants who:

* Are healthy infants
* Aged 42 to 98 days of age at the time of consent.

Infants will receive either 20vPnC or 13vPnC. Doses will be given at approximately 2, 4, and 6 months of age (Doses 1 through 3). A fourth dose will be given at 12 to 15 months of age. Infants will receive the same vaccine (20vPnC or 13vPnC) for all 4 doses.

The total time of the study will be about 16 to 19 months. A subset of infants will be asked to stay in the study for longer.

Conditions

  • Pneumococcal Diseases

Interventions

BIOLOGICAL

20vPnC

20vPnC vaccine

BIOLOGICAL

13vPnC

13vPnC vaccine

Sponsors & Collaborators

Principal Investigators

  • Pfizer CT.gov Call Center · Pfizer

Study Design

Allocation
RANDOMIZED
Purpose
PREVENTION
Masking
TRIPLE
Model
PARALLEL

Eligibility

Min Age
42 Days
Max Age
98 Days
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2026-07-25
Primary Completion
2028-11-30
Completion
2031-05-31

Countries

  • China

Study Locations

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT07754539 on ClinicalTrials.gov